- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07939529
People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35222
- Alabama (Site ID: 31788)
-
Contact:
- Heather Logan
- Telefoonnummer: 205-934-6774
- E-mail: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, Verenigde Staten, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
Contact:
- Aleen Khodabakhshian
- Telefoonnummer: 310-557-3798
- E-mail: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, Verenigde Staten, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
Contact:
- Dawn Rosenblum
- Telefoonnummer: 619-543-8080
- E-mail: drosenblum@health.ucsd.edu
-
San Francisco, California, Verenigde Staten, 94110
- University of California, San Francisco (Site ID: 801)
-
Contact:
- Jay Dwyer
- Telefoonnummer: 415-502-5748
- E-mail: jay.dwyer@ucsf.edu
-
Torrance, California, Verenigde Staten, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
Contact:
- Mario Guerrero
- Telefoonnummer: 323-457-1459
- E-mail: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- University of Colorado Hospital (Site ID: 6101)
-
Contact:
- Nicola Haakonsen
- Telefoonnummer: 303-724-5931
- E-mail: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
Contact:
- Avery Wimpelberg
- Telefoonnummer: 202-797-3589
- E-mail: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University (Site ID: 2701)
-
Contact:
- Sherryl L Wolfe
- Telefoonnummer: 312-695-4997
- E-mail: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University (Site ID: 201)
-
Contact:
- Rebecca L Becker
- Telefoonnummer: 410-614-4036
- E-mail: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital (Site ID: 101)
-
Contact:
- Amy Sbrolla
- Telefoonnummer: 617-726-5598
- E-mail: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, Verenigde Staten, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
Contact:
- Hannah Jordan
- Telefoonnummer: 617-732-4785
- E-mail: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, Verenigde Staten, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
Contact:
- Christie Lyn Costanza
- Telefoonnummer: 972-972-9069
- E-mail: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, Verenigde Staten, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
Contact:
- Mauricio Vergara
- Telefoonnummer: 212-746-7204
- E-mail: mav9177@med.cornell.edu
-
New York, New York, Verenigde Staten, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
Contact:
- Keisha Ballentine-Cargill
- Telefoonnummer: 212-746-7804
- E-mail: keb4006@med.cornell.edu
-
New York, New York, Verenigde Staten, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
Contact:
- Brett T Gray
- Telefoonnummer: 212-305-1570
- E-mail: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27599-7215
- Chapel Hill (Site ID: 3201)
-
Contact:
- Erin Elizabeth Hoffman
- Telefoonnummer: 919-843-0720
- E-mail: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, Verenigde Staten, 27401-1020
- Greensboro (Site ID: 3203)
-
Contact:
- Kelly Phillips
- Telefoonnummer: 336-832-7297
- E-mail: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Contact:
- Michelle Saemann
- Telefoonnummer: 513-584-2245
- E-mail: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, Verenigde Staten, 44106
- Case Clinical Research Site (Site ID: 2501)
-
Contact:
- Julie Pasternak
- Telefoonnummer: 216-844-2738
- E-mail: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, Verenigde Staten, 43210
- Ohio State University (Site ID: 2301)
-
Contact:
- Lindsay Summers
- Telefoonnummer: 614-293-8529
- E-mail: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- University of Pittsburgh (Site ID: 1001)
-
Contact:
- Stacey Edick
- Telefoonnummer: 412-383-1748
- E-mail: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
Contact:
- Beverly Woodward
- Telefoonnummer: 615-936-8516
- E-mail: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
Contact:
- Maria Laura Martinez
- Telefoonnummer: 713-500-6718
- E-mail: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- University of Washington Positive Research (Site ID: 1401)
-
Contact:
- Allysson Angeldekao
- Telefoonnummer: 503-715-7324
- E-mail: allysson@uw.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Tijdsspanne: Baseline through Week 48
|
Baseline through Week 48
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tijdsspanne: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tijdsspanne: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tijdsspanne: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Tijdsspanne: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Tijdsspanne: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Tijdsspanne: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tijdsspanne: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tijdsspanne: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tijdsspanne: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
Tijdsspanne: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Tijdsspanne: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
Tijdsspanne: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
Tijdsspanne: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
Tijdsspanne: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
Tijdsspanne: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Tijdsspanne: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Tijdsspanne: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tijdsspanne: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tijdsspanne: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tijdsspanne: Week 48
|
Week 48
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- A5431
- 39159 (Andere identificatie: DAIDS-ES ID)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data that underlie results in the publication after deidentification
IPD-tijdsbestek voor delen
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD-toegangscriteria voor delen
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .